Evidence map›Paper›PMID 42318371›Full record

ArticleJournal of virus eradication2026

Antiviral efficacy of LNP-delivered IFN-α14-ApoAI mRNA for chronic hepatitis B.

Qunling Yang, Qiang Li, Jie Cao, Conglin Zhao, Mengxin Lu, Shuangshuang Sun, Mingsheng Chen, Chong Chen, Yuxian Huang, Shuai Tao and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virus eradication, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Qunling YangThe Diagnosis and Treatment Center of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, No. 2901 Caolang Road, Jinshan District, Shanghai, China.
Qiang LiThe Diagnosis and Treatment Center of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, No. 2901 Caolang Road, Jinshan District, Shanghai, China.
Jie CaoThe Diagnosis and Treatment Center of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, No. 2901 Caolang Road, Jinshan District, Shanghai, China.
Conglin ZhaoThe Diagnosis and Treatment Center of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, No. 2901 Caolang Road, Jinshan District, Shanghai, China.
Mengxin LuThe Diagnosis and Treatment Center of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, No. 2901 Caolang Road, Jinshan District, Shanghai, China.
Shuangshuang SunThe Diagnosis and Treatment Center of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, No. 2901 Caolang Road, Jinshan District, Shanghai, China.
Mingsheng ChenDepartment of Basic Research, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Chong ChenDepartment of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Yuxian HuangThe Diagnosis and Treatment Center of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, No. 2901 Caolang Road, Jinshan District, Shanghai, China.
Shuai TaoDepartment of Basic Research, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
Liang ChenThe Diagnosis and Treatment Center of Liver Disease, Shanghai Public Health Clinical Center, Fudan University, No. 2901 Caolang Road, Jinshan District, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic hepatitis B virus (HBV) infection remains a major global health burden, and current therapeutic options such as pegylated interferon-α (PEG-IFNα) yield limited clinical efficacy. Here, we developed a lipid nanoparticle (LNP) formulation encapsulating mRNA encoding an IFN-α14-ApoAI fusion protein and evaluated its anti-HBV activity and safety profile in humanized IFNAR mouse models. First, adeno-associated virus (AAV)-mediated delivery of IFN-α14-ApoAI provided preliminary evidence of safe and sustained HBV suppression in mice, suggesting the feasibility of gene delivery of this fusion protein for anti-HBV therapy. On this basis, we formulated IFN-α14-ApoAI mRNA into SM-102-based LNPs, designated as IFN-α14 LNP. A single intravenous injection of this LNP formulation showed a trend toward dose-dependent reduction of HBV antigens. Furthermore, a single intravenous dose of 4 μg IFN-α14 LNP showed comparable inhibition of HBV antigens to the clinically approved drug PEG-IFNα2 (2 μg, subcutaneously). Moreover, safety assessment showed that the 4 μg dose was well tolerated with no detectable organ toxicity, only transient and self-limited cytokine elevations, and reversible splenic immune activation. In addition, repeated dosing of IFN-α14 LNP in mice induced neutralizing antibodies against the xenogeneic human IFN-α14, a limitation that is not anticipated in humans due to immune tolerance to self-proteins. Collectively, our findings demonstrate that IFN-α14 LNP exerts anti-HBV activity while exhibiting a favorable safety profile in humanized IFNAR mouse models. It represents a novel therapeutic candidate for chronic hepatitis B that still requires refinement.

Indexed as

Hepatitis B virusIFN-α14Lipid nanoparticlesmRNA therapyPegylated interferon

Identifiers

PMID42318371
PMCPMC13272520

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.